Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation

Chih Hsien Cheng, Hao Chien Hung, Jin Chiao Lee, Yu Chao Wang, Tsung Han Wu, Chen Fang Lee, Ting Jung Wu, Hong Shiue Chou, Kun-Ming Chan, Wei-Chen Lee*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

1 Scopus citations


BACKGROUND Taiwan has a high prevalence of hepatitis B virus (HBV) infection. HBV-related end-stage liver disease is the leading cause of liver transplantation (LT). Tenofovir alafenamide (TAF) is a recently approved agent for the treatment of chronic HBV infection that improves renal profiles compared with tenofovir disoproxil fumarate (TDF) in phase III trials. This study aimed to assess the outcomes of TAF treatment in LT recipients. MATERIAL AND METHODS This retrospective study analyzed 17 LT recipients who underwent treatment with TDF and TAF. Changes in baseline renal function were compared. RESULTS Seventeen LT recipients received TDF for ≥48 weeks and were switched to TAF. During TDF treatment, estimated glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease [MDRD] formula) decreased significantly at weeks 24 and 48. At week 48, only 2 patients (11.8%) displayed improved renal function, whereas the other patients showed decreased eGFR ranging from 5.48% to 62.84%. After switching to TAF, the median eGFR increased by 3.01% at week 24 and decreased by 0.31% at week 48. Seven patients (47%) showed improved renal function at week 48 after TAF treatment. CONCLUSIONS Switching from TDF to TAF was associated with fewer short-term renal impairment while maintaining the antiviral efficacy in LT recipients.

Original languageEnglish
Article numbere938731
Pages (from-to)e938731
JournalAnnals of Transplantation
StatePublished - 21 04 2023

Bibliographical note

Publisher Copyright:
© Ann Transplant, 2023.


  • Hepatitis B
  • Liver Transplantation
  • Adenine/therapeutic use
  • Hepatitis B, Chronic
  • Humans
  • Alanine/therapeutic use
  • Antiviral Agents/therapeutic use
  • Retrospective Studies
  • Liver Transplantation/adverse effects
  • Hepatitis B/drug therapy
  • Hepatitis B virus
  • Tenofovir/therapeutic use


Dive into the research topics of 'Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation'. Together they form a unique fingerprint.

Cite this